IMPORTANCE OF PARALLEL IMPORTATION OF PATENTED MEDICINES DUE TO ONGOING COVID-19 CRISIS

Rakshita Singh & Nivedita Singh, Army Law College, Pune


CLICK HERE TO VIEW THE FULL RESEARCH PAPER


ABSTRACT


The second wave of Covid-191 has brought about havoc in the healthcare system. The shortage of medicines such as Remdesivir2 has resulted in the denial of proper medical treatment to numerous patients. Medicines are patented due to the intellectual efforts, research, and labor of the R&D department of a company. However, in the current public health crisis, should monopoly rights that cover every aspect of Covid-19 response from vaccines to medicines be given priority over public policy? Granting compulsory licenses to other manufacturers is another way to go about it, but this would prolong the pandemic as it takes time to introduce fresh stock to the market and the requirement is immediate. This article deals with two crucial questions, how parallel importation of patented medicines is an immediate solution to the current crisis and how our Patents Act, 19703 is robust enough to deal with it.


Keywords: Remdesivir, Covid-19, Compulsory License, Monopoly Rights, Public Policy, Parallel Importation, Patents Act.

Journal Details
Abbreviation: NLR 

ISSN:   2582-8479 (O)

Year of Starting: 2020

Place: New Delhi, India

Accessibility: Open Access

Peer Reviewer: Double Blind

Licensing:

 

​All research articles published in NLR and are fully open access. i.e. immediately freely available to read, download and share. Articles are published under the terms of a Creative Commons license which permits use, distribution, and reproduction in any medium provided the original work is properly cited.

1200px-Open_Access_logo_PLoS_transparent.svg.png
NYAAYSHASTRA_Law_Review-removebg-preview.png
Journal Archives
Top Publications